Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study. Clinics. 2021;76:e2251. doi:10.6061/clinics/2021/e2251